THE National Biosafety Board (NBB) met and granted approval for the Institute of Medical Research’s application to conduct a limited mark-release-recapture field trial of the genetically-modified (GM) Aedes aegypti mosquito OX513A(My1) strain early last month.
However, based on the advice of its Genetic Modification Advisory Committee, the approval is subject to the following terms and conditions.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
